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Background: Vitamin D (VD), an important factor for bone health immobilization and
immune regulation, has been shown to have low serum concentration in multiple sclerosis
(MS) patients. Those patients have also multiple fracture risk factors, including progressive
immobilization and long-term glucocorticoids treatment. The aim of the study was to
analyze bone health (osteopenia or osteoporosis prevalence) and VD serum concentration
in MS patients as well as the inﬂuence of disease activity and treatment on bone health.
Materials and methods: The study involved 72 MS patients: 52 women and 20 men. Mean age
was 40.3  10.5 yrs, mean EDSS (Expanded Disability Status Scale) 3.3  1.9. Bone health was
analyzed using standard densitometry in the lumbar spine and femoral neck. Serum levels
of VD, calcium, phosphate and parathormone were assessed. We compared two groups of
patients with multiple sclerosis: relapsing - remitting MS (RRMS) and progressive relapsing
MS (PRMS).
Results: Densitometry revealed osteopenia in twenty-six (36.1%) patients and osteoporosis
in eleven (15.3%), no bone fractures were presented. Sixty-eight MS patients (94.4%) had
lower VD serum level if compared to population referential values. Thirteen patients (18.1%)
had severe VD deﬁciency. Densitometry parameter (T-score of the lumbar spine) worsened
with EDSS increase (r = 0.43, P = 0.001). There was a statistically signiﬁcant negative
correlation between VD concentration and EDSS score (r = 0.31; P = 0.009).
Conclusions: Our study indicates that patients with MS have high incidence of osteopenia
and osteoporosis and vitamin D deﬁciency. Bone health disturbances studied by densitom-
etry are related to the disability caused by MS.
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Multiple sclerosis (MS) is a chronic progressive, inﬂammatory
and demyelinating disease of the central nervous system.
Disease onset usually occurs in early adulthood, and MS is
more common in women. Patients can suffer from various
neurological symptoms and signs, including visual and
pyramidal signs, cranial nerve disturbances, cerebellar, sen-
sory and bowel or bladder dysfunction, as well as cognitive
impairment. Symptoms may worsen with disease progression,
leading to disability and immobilization.
It is suspected that environmental factors, such as sunlight
exposure, play a crucial role in the disease etiopathogenesis.
The results of several studies suggest that low exposure to
sunlight correlates with higher MS prevalence [1,2] and that
the role of UVB light in vitamin D synthesis is critical for this
phenomenon [3].
Although vitamin D and its metabolites are widely known
to be vital for calcium homeostasis [4], they also play a very
important role in the modulation of the immune response.
Low vitamin D concentration correlates with higher MS
prevalence [5]. Vitamin D promotes an anti-inﬂammatory
response by increasing the activity of regulatory lymphocytes.
It also inhibits the proliferation of CD4+ T cells and MBP
speciﬁc T cells. Active vitamin D metabolites reduce the
number of IL-6- and IL-17-secreting cells and increase the
number of Il-10-secreting cells. The presence of active vitamin
D metabolites increases the number of vitamin D receptors on
both inhibited and activated cells and enhances 2,3-deox-
ygenase expression. This enzyme is crucial for the increase in
regulatory cell number (CD4+ and CD25+) [6,7].
It is unknown that why patients with MS have lower
vitamin D concentrations [8]. It might be caused by a
combination of low dietary vitamin D intake and reduced
sunlight exposure. MS symptoms may worsen due to heat,
leading patients to avoid the sun. Reduced sun exposure might
also be caused by increasing disability and immobilization
during MS progression. There is a direct link between sunlight
exposure and vitamin D synthesis in the skin.
Osteoporosis is a progressive bone disease that is charac-
terized by a decrease in bone mass and density, which can lead
to an increased risk of bone fractures. Dual-energy X-ray
absorptiometry (DXA) plays an important role in the diagnosis
of osteoporosis and increased fracture risk. The densitometry
diagnostic criterion of osteoporosis is the reduction of bone
density of the proximal femur or lumbar spine expressed as a
T-score ≤ 2.5.
There is also strong evidence supporting a link between T
cell activity and bone loss during estrogen deﬁciency. These
data are consistent with the interactions of vitamin D and the
immune system and suggest that a low concentration of
vitamin D might act as a proinﬂammatory factor [9].
In MS, osteoporosis risk may be related to impaired
mobility, lack of physical activity, and low VD levels. All of
these factors, especially progressive immobilization, can lead
directly to bone health disturbances [10–12].
The aims of this project were to study bone health in MS
patients using densitometry, clinical and biochemical param-
eters, and vitamin D serum concentration and to ﬁnd anassociation between disease activity and bone health. We
compared two groups of MS patients: relapsing-remitting MS
(RR MS) and progressive-relapsing MS (PR MS).
2. Patients and methods
The Bioethical Committee approved this study. Participants
provided written consent to participate in this study. Partici-
pants received a questionnaire that included information
about the study, read the information and, after speaking with
a doctor, agreed to participate. Both, blood tests and DXA were
performed during their hospitalization.
Seventy-two patients (52 females and 20 males; mean age
40.3  10.5 yrs (ranges: 21–58 yrs)) with a conﬁrmed diagnosis
of MS, according to the McDonald and Polman criteria [13],
were included in the study. All patients were recruited from
the Department of Neurology. The mean EDSS (Expanded
Disability Status Scale) score was 3.3  1.9 (ranges: 1.0–8.5).
Forty-two patients suffered from relapsing-remitting MS (RR
MS). Thirty patients had progressive MS: twenty-two patients
had progressive-relapsing MS (PR MS) and eight had second-
ary-progressive MS (SP MS). Finally in this study, we compared
two groups of patients: RR MS and PR MS. The SP MS group was
not included because of the small number of patients. The
medical history of all patients included intravenous adminis-
tration of methylprednisolone (5 g/treatment) at least once in
the year prior to the study. Fifty-eight patients received long-
term disease modifying therapy including beta interferons
(IFN-b), glatiramer acetate, or immunosuppressive treatment.
The majority of the patients were treated with immunosup-
pressive drugs (32 with mitoxantrone and 5 with cyclophos-
phamide). The rest of the patients (n = 24) were treated with
immunomodulating drugs; 16 received IFN-b, 8 received
glatiramer acetate, and one received natalizumab. Ten
patients remained without chronic immunotherapy.
Bone health was assessed with DXA (Discovery A, Hologic)
in the lumbar spine (L1-L4 in the AP projection) and the
proximal femur (femoral neck) and was presented as a T-score.
T-score values of 2.5 or lower were deﬁned as osteoporosis,
and T-score values lower than 1.0 and higher than 2.5 were
deﬁned as osteopenia. Additionally we evaluated the inci-
dence of low-energy bone fractures studying the patients'
medical histories.
Laboratory tests included serum concentrations of vitamin
D, calcium, and intact parathyroid hormone (intact-PTH)
levels. 25 hydroxyvitamin D3 isoform was measured. 25-
hydroxyvitamin D concentration was assessed by a chemilu-
minescence immunoassay with standard kits Liaison. Other
biochemical parameters in blood were assessed using routine
laboratory methods.
There was no control group. In our analysis, the vitamin D
concentrations in MS patients were compared to a reference
group [14]. Population referential values for vitamin D
concentration in the serum (matched for age) ranged from
30 to 80 ng/ml. A slight vitamin D deﬁciency ranged from 20 to
30 ng/ml, a moderate vitamin D deﬁciency was 10–20 ng/ml,
and a severe VD deﬁciency ranged from 0 to 10 ng/ml [14]. Our
assessment of vitamin D level was performed in winter
(December and January) and in summer (July, August). We
Fig. 1 – The correlation between the densitometry results: T-
scores of the lumbar spine and EDSS scores in patients
with multiple sclerosis (r = S0.43; P = 0.001).
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seasonal variation. In our project we based on recommenda-
tions for Central Europe. These guidelines do not take into the
consideration a seasonal variability of VD concentrations [15].
To exclude other pathologies that could affect bone health,
thyroid hormone status, renal parameters, BMI (body mass
index) and life style choices such as smoking were analyzed.
Patients were not included in the study if those parameters
were abnormal.
Statistical analyses were performed using the SAS System
version 9.3. Data are presented as the mean  standard
deviation. Associations between quantitative variables were
investigated using Pearson's rank correlation test. Statistical
signiﬁcance was established as P < 0.05. A comparison of MS
patients groups with relapsing-remitting MS (RR MS) and
progressive-relapsing MS (PR MS), in terms of quantitative
parameters, was performed using the Mann–Whitney test.
3. Results
Densitometry revealed bone health abnormalities in 37
patients (51.4%): osteopenia in twenty-six patients (36.1%),
and osteoporosis in eleven patients (15.3%). Densitometry of
the proximal femur showed osteoporosis in 9 patients (12.5%)
and osteopenia in 20 patients (27.8%). Densitometry of the
lumbar spine revealed osteoporosis in 7 patients (9.7%), and 24
patients (33.3%) had osteopenia. According to patients'
medical history, no low-energy bone fractures had occurred
in the study group.
Sixty-eight (94.4%) patients had low serum vitamin D levels
(<30 ng/ml), and in 13 of those patients (18.1%), the deﬁcit was
severe (<10 ng/ml). The means vitamin D concentration in MS
patients was 18.8 ng/ml and was signiﬁcantly lower than
referential values. The mean vitamin D concentration was
12.84 ng/ml in winter and 21.93 ng/ml in summer. Patients
with osteoporosis conﬁrmed by densitometry had a lower
vitamin D concentration (mean: 13.1 ng/ml) than patients with
osteopenia (mean: 21.9 ng/ml). No signiﬁcant abnormalities
were found in calcium and phosphate serum concentrations.
Ten patients (13.9%) had abnormal PTH concentrations; six of
those patients had high PTH levels (>65 pg/ml), and 4 had low
PTH levels (<15 pg/ml). The mean BMI was 23.6 kg/m2. BMI did
not correlate with BMD. Among the 72 patients no one smoked.
Densitometry parameters (T-scores of the lumbar spine but
not the femoral neck) worsened as EDSS increased (r = 0.43;
P = 0.001) (Fig. 1). There was a statistically signiﬁcant negative
correlation between VD concentration and EDSS score
(r = 0.31; P = 0.009) (Fig. 2). We did not ﬁnd any correlation
between vitamin D serum concentration and disease duration
(P = 0.46) and densitometry parameters (P = 0.34). There was no
correlation between serum PTH concentration, densitometry
parameters, and EDSS scores.
According to our results, the median vitamin D concentra-
tion was signiﬁcantly lower in PR MS patients than in RR MS
patients (10.3 ng/ml vs. 15.8 ng/ml, P = 0.004). This result might
be explained by signiﬁcant age differences; patients who
suffered from PR MS were older than those who suffered from
RR MS (P = 0.0068). Moreover, there was a signiﬁcant difference
in the degree of disability. Patients with PR MS scoredsigniﬁcantly higher in the EDSS; the mean EDSS score was
in this group 5.0, while in RR MS patients it was signiﬁcantly
lower (mean EDSS = 2.0).
When we compared these two groups of MS patients
separately, we did not ﬁnd any signiﬁcant correlation between
the densitometry parameter (T-score of the lumbar spine) and
the EDSS score (P = 0.310 for PR MS patients; P = 0.072 for RR MS
patients). Vitamin D concentration did not correlate with EDSS
score in either PR MS patients (P = 0.380) nor in RR MS patients
(P = 0.21).
Patients in the PR MS group with longer disease duration
have a signiﬁcantly increased risk of osteoporosis; the median
T-score of the proximal femur was in this group was 1.1
compared to RR MS patients, where it was 0.6 (P = 0.0426).
Demographic data of MS patients are presented in Table 1.
Laboratory and clinical data are shown in Table 2.
4. Discussion
According to our results, the bone health studied with DXA has
revealed abnormalities in MS patients. However it is difﬁcult to
conclude whether the BMD loss is lower in MS patients than in
the general population. Moen et al. have found high preva-
lence of low bone mass in patients with MS and in the general
population as well. They measured BMD at early stages of
Fig. 2 – The correlation between serum concentrations of
vitamin D (ng/ml) and EDSS scores in patients with
multiple sclerosis (r = S0.31; P = 0.009).
Table 1 – MS patients. Demographic data.
Variable Progressive-relapsing MS
(n = 22)
F: 10; M: 10
Median Q1–Q3 
Age (years) 45 36–53 
EDSS 5 3.5–5.5 
MS duration (years) 9 8–12 
EDSS – Expanded Disability Status Scale; F – females; M – males; MS – m
* Statistically signiﬁcant difference.
Table 2 – MS patients. Laboratory data.
Variable Progressive-relapsing
(n = 22)
F: 10; M: 10
Median Q1–
DXA (T-score of the lumbar spine) 1 1.7 t
DXA (T-score of the proximal femur) 1.1 1.9 t
Serum vitamin D (ng/ml) 10.3 8.34–1
Serum calcium (mg/dl) 2.33 2.29–2
Serum PTH (mg/dl) 42.74 31.9–5
DXA – densitometry; F – females; M – males; MS – multiple sclerosis; PT
* Statistically signiﬁcant.
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patients with multiple sclerosis with long-standing disease.
But in this study, low bone mass was appeared early in MS.
This ﬁnding is compatible with the hypothesis that MS and
osteoporosis share etiological factors, and the bone deﬁcit in
the newly diagnosed patients could be explained by low bone
mass before disease onset [16].
In our study, densitometry revealed that 36.1% of patients
had osteopenia. The prevalence of osteoporosis reached 15.3%.
This ﬁnding could be attributed to disability and the prolonged
immobilization of patients, as both are well known risk factors
for bone mass loss. Densitometry parameters (T-score of the
lumbar spine but not of the proximal femur) worsened as EDSS
increased. Our results are in line with those from other studies.
Khachanova et al. reported that reduced bone mineral density
in the lumbar spine and femoral neck is associated with a
higher EDSS score and is caused by the combination of
moderate pyramidal and cerebellar dysfunction [17].
Immobility as a major factor of BMD loss was suggested by
Ayatollahi et al. Their results showed that BMD was
signiﬁcantly lower in MS patients with higher EDSS score
and longer disease duration. Moreover, femoral BMD was
signiﬁcantly lower among MS patients than age matched
controls [18].
Some literature data suggest that MS patients have higher
risk for osteoporosis. Coskun et al. determined risk factors of
low BMD in patients with MS. Of the 67 patients, 20.9% revealed
low BMD on femoral neck densitometry. Longer disease
duration with severe disability led to lower BMD [19].
To give an impression that the prevalence of bone
deﬁciency is actually higher in MS patients we cite the
meta-analysis of Huang et al. This analysis shows that MSRelapsing-remitting MS
(n = 42)
F: 29; M: 13
P-value
Median Q1–Q3
36 28–47 0.0068*
2 1.3–3.0 0.0000*
5.5 4–9 0.0003*
ultiple sclerosis; Q1, Q3 – quartiles.
 MS Relapsing-remitting MS
(n = 42)
F: 29; M: 13
P-value
Q3 Median Q1–Q3
o 0 0.3 1.1 to 0.2 0.1376
o 0.4 0.6 1.3 to 0.3 0.0426*
6.7 15.8 11.5–21.31 0.0049*
.38 2.345 2.24–2.38 0.7824
2.8 32.93 27.87–42.54 0.0491*
H – parathyroid hormone; Q1, Q3 – quartiles.
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healthy controls. Furthermore disease duration over 7 years,
glucocorticosteroids administration as well as EDSS over 3 are
risk factors for reduced BMD [20].
Obtained results suggest that there is a strong evidence that
MS is associated with an increased risk of osteoporosis. It can
be related to the cumulative effects of various factors, such as
physical inactivity and reduced mechanical load on the bones
(offsetting gravity). Another possible risk factor of osteoporosis
is low vitamin D levels. The role of the inﬂammatory processes
related to the underlying disease is considered in the context
of complex bone metabolism [21].
Most epidemiological studies suggest that vitamin D
deﬁciency is frequent in central European populations [14].
Seasonal variability of vitamin D serum concentrations is
reported by many authors although obtained results are
heterogeneous and still discussed. We based on recommenda-
tions (published in 2013) for serum vitamin D concentrations.
The authors of these guidelines did not taken into the
considerations the data related to the seasonal variability [15].
In the literature, vitamin D deﬁciency has been reported in
approximately 70% of seriously disabled patients with MS. The
results of a meta-analysis conﬁrm also that MS patients had
decreased mean levels of vitamin D [22].
In some paper we may found also an opinion that vitamin D
status did not differ signiﬁcantly between MS patients and
controls [23].
On the other hand, there are some studies which conﬁrm
our results. Thirty-one patients with MS and thirty matched
healthy controls were participated in this study. MS patients
had signiﬁcantly lower vitamin D levels (17.3 ng/ml vs 43.1 ng/
ml; P < 0.001) compared to controls. Moreover, those patients
had also signiﬁcantly lower BMD at the lumbar spine and
femur trochanter densitometry if compared to the matched
controls [24].
In another one, levels of vitamin D were also lower in MS
patients than controls. Such a result was explained by
differences in climate and geography. In contrast to our
results, there was no association between vitamin D status
and disease severity [25].
Harandi et al. reported that vitamin D could be involved in
the regulation of clinical disease activity in MS patients, based
on its inverse correlation with disease severity measured using
EDSS scores [26]. Shahbeigi et al. also found a signiﬁcant
correlation between lower VD status and higher EDSS [27]. Our
study conﬁrms the possible importance of vitamin D status in
patients with MS and its association with disease severity.
Patients with higher scores on EDSS had lower levels of serum
vitamin D (P = 0.009). It is, however, difﬁcult to explain whether
VD deﬁciency is a pathogenic factor for MS or if vitamin D
simply decreases with the patient's increasing disability.
However, obtained results seem to conﬁrm the inﬂuence of
disease activity on bone health.
In the literature we have found also a study performed on
polish population. This report conﬁrmed signiﬁcantly lower
vitamin D concentrations among MS patients compared to
controls. Moreover, in patients with longer disease duration
(5–6 years) this concentration was lower than patients at the
early stage of MS. These results conﬁrm our observation.
Patients in the PR MS group with longer disease durations hadsigniﬁcantly lower vitamin D concentration. Patients with
early MS had higher vitamin D levels [28].
It is important to point out that use of dietary supplements
including vitamin D did not affect the vitamin D concentra-
tions in both groups of MS patients. Moreover, vitamin D
supplementation did not prevent bone loss over a 2-year
observation period in a placebo controlled trial. Percentage
change in BMD did not differ between participants who had
received vitamin D and who had received placebo [29].
Vitamin D plays a role in the pathogenesis and prevention
of several diseases other than MS, such as cancer, cardiovas-
cular diseases, diabetes, rheumatoid arthritis, and other
autoimmune diseases. Meta-analyses and systematic reviews
have revealed an association between vitamin D insufﬁciency
or deﬁciency and diseases that do not affect directly the bone
health [30].
In this study, we noted decreased vitamin D levels. Patients
with osteoporosis had lower VD concentrations than patients
with osteopenia (the mean concentration of vitamin D in the
ﬁrst group was 13.1 ng/ml vs. 21.9 ng/ml in MS patients with
osteopenia). A more pronounced vitamin D insufﬁciency was
observed in patients with RP MS. In this group of patients, low
VD values can be associated with low sunlight exposure that
was caused by increasing disability and immobilization during
related to the disease progression. It might also be explained
by signiﬁcant age differences; patients who suffered from PR
MS were older than those with RR MS (P = 0.0068). Analyzing T-
score or vitamin D concentration with EDSS in those groups we
did not ﬁnd any signiﬁcant correlation. This fact could be
explained by the low number of those patients in our material.
Glucocorticoids are frequently used to treat MS relapses.
Glucocorticoid-induced osteoporosis is the main type of
secondary osteoporosis and leads to fractures far more often
than postmenopausal osteoporosis. Epidemiological studies
have shown that fracture risk has increased rapidly after the
onset of oral glucocorticoid treatment and was related to the
dose and duration of glucocorticoid exposure [31]. Prolonged
oral corticosteroid treatment using more than 5 mg of
prednisolone (or equivalent) daily leads to a reduction in bone
mineral density and a rapid increase of fracture risk during the
treatment period [32].
Glucocorticoids are widely used for the chronic treatment
of autoimmune inﬂammatory diseases, such as rheumatoid
arthritis. Overall, current evidence supports the thesis that
bone loss is a disease independently related to both rheuma-
toid arthritis and glucocorticoid use [33].
In our study, all tested patients received only short-lasting,
high-dose-methylprednisolone therapy at least once in the
year prior to the study. Intravenous infusions of high-dose
methylprednisolone in MS patients did not result in a severe
decrease in densitometric parameters.
Another study revealed that MS patients who have received
short-term high-dose glucocorticoids treatment are not at
increased risk of low bone mass. BMD was compared to a
healthy age-matched reference population [34]. The ﬁndings
cohere with ours. Glucocorticosteroids treatment did not seem
to be a cause of secondary osteoporosis in MS patients.
Zorzon et al. [35] support this observation. Osteopenia was
found only in patients treated for relapses (they received
steroids for a short time), and they had a signiﬁcantly
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depends more on disease activity than on glucocorticosteroid
administration.
In Poland, there are no precise epidemiological data about
prevalence of osteoporosis/osteopenia in the general popula-
tion. We found only the information on the incidence of hip
fractures in Poland. This study was however conducted on a
large number of patients. The results of this study conﬁrmed
the high incidence of hip fractures in Poland [36].
It is shown in the literature that bone fractures can occur
more often in patients with MS. According to Bazelier et al.,
patients with MS have an increased risk of osteoporotic
fractures, especially hip fractures. The risk was higher in
patients who had recently used oral or intravenous gluco-
corticosteroids or antidepressants [37,38]. In our study, no
patients had low-energy bone fractures in their medical
histories, perhaps because our study group consisted on
relatively young patients (mean age was 40.3  10.5 yrs).
5. Conclusions
According to our results, patients with multiple sclerosis have
a high incidence of osteopenia, osteoporosis and vitamin D
deﬁciency. Osteopenia occurs more often than osteoporosis.
Densitometry parameters (T-score of the lumbar spine)
worsened as EDSS increased. Vitamin D negatively correlated
with EDSS score.
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